Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
29.4M
-
Shares change
-
+225K
-
Total reported value, excl. options
-
$346M
-
Value change
-
+$3.16M
-
Put/Call ratio
-
0.83
-
Number of buys
-
57
-
Number of sells
-
-43
-
Price
-
$11.77
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q4 2021
124 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q4 2021.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.4M shares
.
Largest 10 shareholders include PICTET ASSET MANAGEMENT SA (3.55M shares), BlackRock Inc. (3.48M shares), HHLR ADVISORS, LTD. (2.92M shares), VANGUARD GROUP INC (2.89M shares), BAKER BROS. ADVISORS LP (2.8M shares), STATE STREET CORP (1.47M shares), ArrowMark Colorado Holdings LLC (1.27M shares), Hudson Bay Capital Management LP (1.05M shares), Opaleye Management Inc. (1.03M shares), and RICE HALL JAMES & ASSOCIATES, LLC (713K shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.